LLY and NVON Related Headlines
Go Back- M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip
- Novo Nordisk: Diabetes and obesity GLP-1 portfolio still attractive says Bernstein
- UBS slashes global GLP-1 sales estimate for 2030 on softer outlook
- Novo Nordisk's Wegovy may quiet thoughts about food, study shows; shares up
- Hims&Hers gains after court rejects Eli Lilly’s case against Willow
- LLY obesity data seen as small sentiment hit for NVO, no major change—Barclays
